Drug Type Synthetic peptide |
Synonyms SOR C13 |
Target |
Mechanism TRPV6 antagonists(Transient receptor potential cation channel subfamily V member antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC72H116N20O19 |
InChIKeyLGANPTNILMNMES-TVNHODDRSA-N |
CAS Registry1187852-48-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Carcinoma | Phase 1 | US | 29 Jul 2019 | |
Prostate Cancer, Hereditary, 7 | Phase 1 | US | 29 Jul 2019 | |
Refractory Malignant Solid Neoplasm | Phase 1 | US | 29 Jul 2019 | |
Refractory Ovarian Carcinoma | Phase 1 | US | 29 Jul 2019 | |
Advanced cancer | Phase 1 | US | 01 Jul 2012 | |
Advanced cancer | Phase 1 | CA | 01 Jul 2012 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Jul 2012 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 01 Jul 2012 |
Phase 1 | 23 | jiyvroizuj(nepexphvpb) = 30% rkxamazrkv (jwijsvbcid ) View more | Positive | 15 Jul 2016 |